PA
NVCR icon

Perceptive Advisors’s NovoCure NVCR Stock Holding History

Perceptive Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-9,489
Closed -$800K – 123
2019
Q4 		$800K Hold
9,489
– – 0.02% 100
2019
Q3 		$710K Buy
+9,489
New +$759K 0.02% 94

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Perceptive Advisors's NVCR Position: Q1 2020 in Review

Perceptive Advisors sold out of NovoCure (NVCR) in Q1 2020, closing a stake of 9,489 shares — an estimated $800K sold.

Perceptive Advisors first reported a position in NVCR in Q3 2019 and held it in 2 quarters. The position peaked at $800K in Q4 2019. 271 funds tracked by Wall St. Rank hold NVCR as of Q1 2020.

  • Perceptive Advisors reported no remaining NovoCure position as of Q1 2020 after selling out during the quarter.
  • Perceptive Advisors sold 9,489 NovoCure shares in Q1 2020, an estimated $800K.
  • Perceptive Advisors first reported a position in NovoCure in Q3 2019 and held it in 2 quarters.
  • Perceptive Advisors's NovoCure position peaked at $800K in Q4 2019.
  • 271 funds tracked by Wall St. Rank held NovoCure as of Q1 2020.

Based on Perceptive Advisors's 13F filing for Q1 2020, filed 15 May 2020.